Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
WakeMed, a three-hospital system in the North Carolina capital region of Raleigh, would become part of Advocate Health, Atrium’s parent company, if the deal goes through. Advocate is one of the largest not-for-profit health systems in the U.S.
The New Jersey-based drug developer joins AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer in offering their products directly to patients at a discounted rate. Johnson & Johnson is currently listing four medications on the platform.
The agency said it is seeking to exclude semaglutide, tirzepatide and liraglutide from the 503B program based on a lack of clinical evidence. Unless there’s a shortage, the pharmaceuticals would be barred from being compounded by third-parties for the purpose of treating diabetes or obesity. The FDA is seeking public comment on the proposal.
Federal regulators alleged that U.S. Anesthesia Partners—a portfolio company of Welsh, Carson, Anderson & Stowes—engaged in a “roll-up scheme” in Texas that effectively eliminated the competition. The company denies the allegations, but has agreed to undisclosed terms that would see the lawsuit resolved.
Over 97% of all counties in the U.S. see high or very high levels of consolidation in Medicare Advantage markets, with UnitedHealthcare and Humana owning the most plans nationwide.
Former Steward Health Care CEO Ralph de la Torre, MD, and other executives are accused in a $1.4 billion legal filing of paying themselves hundreds of millions of dollars in bonuses, despite the health system being insolvent.
In a new report, the New York Times details multiple incidents of the insurance giant using legal threats to silence social media users and news outlets, citing the murder of Brian Thompson and the threat of rising violence as the basis for its claims.
Shareholders of the retail pharmacy giant voted in favor of the terms of the sale to Sycamore Partners for $11.45 a share. The deal is expected to close later this year.
Xealth’s data sharing platform will be used to make use of health information gathered from everyday devices like the Samsung Galaxy Smartwatch, the companies said.